EGFR and lung cancer: Ongoing trials for recurrent or advanced NSCLC will test the efficacy of various combination therapies including EGFR inhibitors, second-generation tyrosine kinase inhibitors, dual MET/VEGFR2 inhibitor, and targeted drugs to different proteins disregulated in lung cancer.